Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults: 11 Years' Experience at Asan Medical Center
暂无分享,去创建一个
Dae-Ho Lee | J. Huh | C. Suh | S. Park | S. Kim | E. Han | Y. Jeong | Y. Bae | Yunjeong Bae
[1] Y. Bang,et al. Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean Institution: Clinical Characteristics and Treatment Outcome , 2006, Journal of Korean medical science.
[2] E. Campo,et al. Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece , 2006, Histopathology.
[3] Y. Kwong,et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] C. Meijer,et al. ALK‐negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects–a review , 2003, The Journal of pathology.
[5] S. Chuang,et al. Anaplastic Large Cell Lymphoma--A Rare Disorder in Southern Taiwan , 2003, Leukemia & lymphoma.
[6] J K Chan,et al. The new World Health Organization classification of lymphomas: the past, the present and the future , 2001, Hematological oncology.
[7] S. Morris,et al. Translocations involving anaplastic lymphoma kinase (ALK) , 2001, Oncogene.
[8] B. Nathwani,et al. Systemic anaplastic large‐cell lymphoma: Results from the non‐Hodgkin's lymphoma classification project , 2001, American journal of hematology.
[9] S. Pileri,et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.
[10] C. Meijer,et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination , 2000, Journal of clinical pathology.
[11] R. Gascoyne,et al. Anaplastic large cell lymphoma: a clinicopathologic analysis , 1999, Hematological oncology.
[12] T. Greiner,et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.
[13] S. Pileri,et al. ALK+ lymphoma: clinico-pathological findings and outcome. , 1999, Blood.
[14] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Gaulard,et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. , 1997, Blood.
[16] M. Gobbi,et al. Anaplastic large cell lymphoma: a clinicopathologic study of 53 patients. , 1996, Leukemia & lymphoma.
[17] S. Pileri,et al. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[19] J. Hainsworth,et al. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Warnke,et al. CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35 , 1990, British journal of haematology.
[21] K. Lennert,et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.
[22] F. Angrilli,et al. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL). , 1999, Haematologica.
[23] F. Stirpe,et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. , 1995, Blood.